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Abstract
The immunosuppressive microenvironment in solid tumors is thought to form a
barrier to the entry and efficacy of cell‐based therapies such as chimeric anti-
gen receptor (CAR) T cells. Combining CAR T cell therapy with checkpoint in-
hibitors has been demonstrated to oppose immune escape mechanisms in solid
tumors and augment antitumor efficacy. We evaluated PD‐1/PD‐L1 signaling
capacity and the impact of an inhibitor of this checkpoint axis in an in vitro
system for cancer cell challenge, the coculture of L1CAM‐specific CAR T cells
with neuroblastoma cell lines. Fluorescence‐activated cell sorting‐based ana-
lyses and luciferase reporter assays were used to assess PD‐1/PD‐L1 expression
on CAR T and tumor cells as well as CAR T cell ability to kill neuroblastoma
cells. Coculturing neuroblastoma cell lines with L1CAM‐CAR T cells upregulated
PD‐L1 expression on neuroblastoma cells, confirming adaptive immune re-
sistance. Exposure to neuroblastoma cells also upregulated the expression of
the PD‐1/PD‐L1 axis in CAR T cells. The checkpoint inhibitor, nivolumab, en-
hanced L1CAM‐CAR T cell‐directed killing. However, nivolumab‐enhanced
L1CAM‐CAR T cell killing did not strictly correlate with PD‐L1 expression on
neuroblastoma cells. In fact, checkpoint inhibitor success relied on strong PD‐1/
PD‐L1 axis expression in the CAR T cells, which in turn depended on costimu-
latory domains within the CAR construct, and more importantly, on the subset
of T cells selected for CAR T cell generation. Thus, T cell subset selection for
CAR T cell generation and CAR T cell prescreening for PD‐1/PD‐L1 expression
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could help determine when combination therapy with checkpoint inhibitors
could improve treatment efficacy.
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1 | INTRODUCTION
Despite the remarkable antitumor potency of CD19‐targeting chimeric
antigen receptor (CAR) T cells against various hematological malig-
nancies, similar results have not yet been achieved against solid tumors
with CAR T cells. Trafficking to the tumor site, tumor recognition, CAR T
cell proliferation, and persistence as well as overcoming the im-
munosuppressive tumor microenvironment present hurdles to CAR T
cell efficacy against solid tumors.1 Programmed cell death 1 (PD‐1,
formally known as PDCD1) is a coinhibitory receptor expressed by
T cells and member of the B7:CD28 family.2 PD‐1 factors into the
immunosuppressive tumor microenvironment, as binding to its ligand,
PD‐L1 (formally known as CD274) leads to a reduction in T cell receptor
downstream signaling and attenuates T cell activation.3‐5 Combining
adoptive CAR T cell therapy with checkpoint inhibition enacted by
monoclonal antibodies against PD‐1 was demonstrated to augment
tumor‐specific T cell efficacy against in vitro and in vivo models of
metastatic melanoma, mesothelioma, and prostate cancer.6‐8 Encoura-
ging results have been achieved by other groups using CRISPR/Cas 9 to
disrupt the endogenous PD‐1 gene or by introducing either a chimeric
PD‐1:CD28 receptor or a truncated PD‐1 receptor lacking the in-
tracellular signaling domain into CAR T cells.9‐12 Research to date de-
monstrates that blockade of the PD‐1/PD‐L1 checkpoint axis shows
promise to boost CAR T cell efficacy against solid tumors.
Less than half the children with high‐risk or relapsed neuro-
blastoma, the most common extracranial solid tumor in childhood,
survive disease despite increasingly aggressive multimodal therapeutic
regimens.13‐15 Immunotherapy has joined the focus of investigators
trying to improve combination therapies for these patient groups. Re-
searchers currently focus on two different neuroblastoma surface an-
tigens, namely, GD2 and L1CAM, for CAR T cell development.16 Our
group previously developed a CAR targeting L1CAM,17 and has begun
to use T cell fractions enriched for central memory T cells (TCM) to
generate CAR T cells, since in vivo studies have shown that TCM‐
derived CAR T cells more actively proliferate and persist longer.18‐20
So far, CAR T cells targeting neuroblastoma and derived either from
TCM or bulk T cells have shown promising antitumor activity in pre-
clinical in vitro and in vivo studies.17,21,22 However, first results from
on‐going clinical trials show only modest or transient responses to both,
mainly because CAR T cell persistence is limiting.23,24 The observed low
T cell infiltration into neuroblastomas classifies them as im-
munologically “cold” tumors25 making a response to checkpoint in-
hibitors unlikely. In contrast, a melanoma microenvironment inflamed
with T cells was demonstrated to indicate responsiveness to PD‐1
checkpoint inhibitors.26 Moreover, INFG‐driven PD‐L1 expression,
previously described as adaptive tumor cell immune resistance,27 was
confirmed in three of four metastatic neuroblast samples derived from
bone marrow aspirates from high‐risk neuroblastoma patients.28 An
encounter with the neuroblastoma‐targeting CAR T cell might cause an
inflamed neuroblastoma microenvironment and induce the PD‐1/PD‐L1
checkpoint signaling axis. Thus, treatment with a checkpoint inhibitor to
cause PD‐1 blockade might augment CAR T cell efficacy and keep the
“cold” neuroblastoma microenvironment immunologically “hot.”
To date, additional to the standard CD3zeta cytoplasmic domain,
four different costimulatory domains (CD28, 4‐1BB, OX40, and CD27)
have been used in second‐generation CAR constructs targeting neu-
roblastoma.16 The type of costimulatory domain incorporated is gen-
erally thought to influence checkpoint signaling through the PD‐1/PD‐
L1 axis. However, recent data have described the contradictory impact
of the CD28 and 4‐1BB costimulatory domains on PD‐1 expression in
CAR T cells.29,30 These findings make predicting the impact of the type
of costimulatory domain expressed in CAR T cells on PD‐1 expression
in neuroblastoma‐targeting CAR T cells difficult, and requires addi-
tional testing to identify CARs benefiting from PD‐1 inhibition. For this
reason, we included CARs using both the CD28 and 4‐1BB costimu-
latory domains in our testing regimen to assess impact on PD‐1/PD‐L1
checkpoint signaling in in vitro models for neuroblastoma cell chal-
lenge with L1CAM‐specific CAR T cells. Our in vitro testing regimen
was designed to select the best candidate CAR targeting the
neuroblastoma‐specific antigen, L1CAM, for a combinational approach
with PD‐1 checkpoint inhibition. We aimed to assess the impact of the
choices of (a) costimulatory domain and (b) starting material for T cell
manufacture on both CAR T cell efficacy and PD‐1/PD‐L1 signaling
induction to evaluate whether nivolumab could augment L1CAM‐
specific CAR T cell efficacy against neuroblastoma cells.
2 | MATERIALS AND METHODS
2.1 | Cell lines
The SK‐N‐BE(2) neuroblastoma cell line (ATCC CRL‐2271) was
lentivirally transduced with PDL1‐T2A‐CD19t_epHIV7.2 before im-
munomagnetic selection with CD19 microbeads (Miltenyi Biotec,
Bergisch Gladbach, Germany) to enrich for transduced cells. Parental
and PD‐L1‐expressing SK‐N‐BE(2) cells, as well as SK‐N‐AS (ATCC
CRL‐2137) and SH‐SY5Y (ATCC CRL‐2266) neuroblastoma cells were
transduced with GFP‐ffLuc_epHIV7. GFP‐expressing cells were
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selected using fluorescence‐activated cell sorting (FACS). Parental and
transduced SK‐N‐BE(2) cells were maintained in Dulbecco's modified
Eagle's medium (DMEM; Gibco Life Technologies, Carlsbad, CA) and
parental and transduced SK‐N‐AS and SH‐SY5Y cells in Roswell Park
Memorial Institute (RPMI) 1640 (Gibco Life technologies) base
medium, supplemented with 10% heat‐inactivated fetal calf serum
(FCS, Sigma‐Aldrich, St. Louis, MO). The TMLCL EBV‐transformed
lymphoblastoid cell line TMLCL was maintained in RPMI 1640 sup-
plemented with 10% heat‐inactivated FCS and 2mM/L of L‐glutamine
(Biochrom, Berlin, Germany). The 293T cell line, used for lentiviral
construct propagation, was cultured in DMEM supplemented with
10% heat‐inactivated FCS.
2.2 | CAR construct
The previously described L1CAM‐specific CE7‐CAR17 was cloned
into the SIN epHIV7 lentiviral vector then propagated in 293T cells
and isolated as previously described.31 The single‐chain variable
fragment in the CAR construct was codon optimized and subse-
quently linked to a 229‐amino acid spacer domain (long spacer)
from the human immunoglobulin (Ig)G4 hinge. The long spacer
domain was modified by substituting L235D and N297Q to reduce
affinity to the IgG Fc gamma receptor (on natural killer cells and
monocytes), which causes unintended CAR T cell activation via
innate immune cell activation.32 The spacer domain connects the
antigen‐binding domain to CD28 transmembrane domain followed
by the signaling module containing the CD3zeta cytoplasmic do-
main and either the 4‐1BB or CD28 (second‐generation CAR)
costimulatory domain. CAR constructs were linked downstream to
a T2A self‐cleaving peptide and a truncated epidermal growth
factor receptor (EGFRt) allowing CAR T cell detection and
enrichment.33
2.3 | L1CAM‐specific CAR T cell generation
CAR T cells were generated from healthy donors (Charité ethics
committee approval EA2/216/18) as previously described.17 Briefly,
apheresis products were obtained and peripheral blood mononuclear
cells were isolated using Ficoll‐Paque (GE Healthcare, Chicago, IL).
CD8+ T cells were obtained by positive selection using im-
munomagnetic microbeads (Miltenyi Biotec). If used for TCM‐derived
CAR T cell generation, CD8+ T cells were further enriched by
CD45RA depletion and SELL positive selection using im-
munomagnetic microbeads (Miltenyi Biotec). Both bulk and TCM‐
enriched CD8+ T cells were activated with anti‐CD3/CD28 beads at a
bead‐to‐cell ratio of 1:1 (Life Technologies). On day 3, activated
CD8+ T cells were transduced with the lentivirus containing the CAR
construct. The EGFRt+ CAR T cell subset was enriched by im-
munomagnetic selection with biotin‐conjugated cetuximab (Bristol‐
Myers Squibb, New York City, NY) and streptavidin microbeads
(Miltenyi Biotec). T cells used as controls alongside CAR T cells in
experiments were not lentivirally transduced. CAR and control T cells
were cryopreserved until further use. Cryopreserved cells were
thawed and stimulated with irradiated peripheral blood mononuclear
cells, irradiated lymphoblastoid TMLCL cells, and 30 ng/mL antibody
activating the CD3 complex (OKT3 clone, Miltenyi Biotec). For rapid
expansion, T cells were maintained in RPMI 1640 media supple-
mented with 10% FCS, interleukin‐15 (IL‐15; 0.5 ng/mL, Miltenyi
Biotec) and IL‐2 (50 U/mL, Novartis, Basel, Switzerland) according to
a rapid expansion protocol.34 Functional in vitro assays were con-
ducted between days 11 and 15 of culture or between days 11 and
25 for the serial tumor challenge.
2.4 | CRISPR‐mediated generation of PD‐L1
knockout in SK‐N‐BE(2) neuroblastoma cells
Guide RNA sequences were designed using Dr. Feng Zhang's on-
line CRISPR design tool35 (http://www.genome‐engineering.org/
crispr/?page_id=41), and targeted CD274 (formerly PD‐L1) exons
2 and 3 to achieve a global knockout (KO) in the SK‐N‐BE(2)
neuroblastoma cell line. Guide RNA sequences were TCTTTA-
TATTCATGACCTAC (PD‐L1‐guide ribonucleic acid [gRNA1]) and
TACCGCTGCATGATCAGCTA (PD‐L1‐gRNA2). Upon gRNA selec-
tion, respective oligonucleotides were annealed and ligated into
the BbsI‐digested CRISPR vector, pSpCas9(BB)‐2A‐Puro (PX459)
V2.0 (donated by Feng Zhang to the Addgene nonprofit plasmid
repository, Watertown, MA). Generated vectors were validated by
sequencing before transfection into neuroblastoma cells using the
Effectene transfection reagent kit (cat #301425, Qiagen, Venlo,
Netherlands) according to the manufacturer's instructions. Briefly,
parental and GFP‐ffLuc_epHIV7‐transduced SK‐N‐BE(2) neuro-
blastoma cells were plated 24 hours before transfection. Trans-
fection reagents (100 µL Effectene buffer,12 1 µg of plasmid DNA,
2 µL Enhancer, and 7.5 µL Effectene) were added to the full media
used for the media change of the plated cells. Selection was con-
ducted using a full medium containing 2 µg/mL of puromycin on
day 3 until day 6. SK‐N‐BE(2) cells with PD‐L1 KO were first sti-
mulated with 100 ng/mL recombinant human interferon‐gamma
(IFNG; PeproTech, Rocky Hill, NJ) in the medium for 24 hours
before being enriched by immunomagnetic depletion using an
APC‐conjugated monoclonal antibody against PD‐L1 (cat
#329708, BioLegend, San Diego, CA) and APC microbeads
(Miltenyi Biotec).
2.5 | In vitro tumor cell cytotoxicity assay in single
and serial challenge
The parental SK‐N‐BE(2), SK‐N‐AS, and SH‐SY5Y cell lines or de-
rived models expressing high‐level (transduced with a lentiviral
vector) or no PD‐L1 (CRISPR‐based gene‐KO) were stably trans-
duced with the GFP‐ffLuc_epHIV7 reporter plasmid to serve as
tumor target cells. Target cells were cocultured in triplicate with
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control T or CAR T cells at a 1:2 or 1:5 effector:target (E:T) ratio
for singular tumor encounter and at a 1:1 E:T ratio during the
serial tumor challenge. Nivolumab (Bristol‐Myers Squibb) is a hu-
man monoclonal IgG‐type antibody against PD‐1. Lyophilized ni-
volumab was reconstituted in 0.9% sodium chloride (NaCl) for a
stock solution, and used at 40 µg/mL culture medium for PD‐1
blockade in functional in vitro assays. CAR T cell‐induced cyto-
toxicity was quantified in a biophotonic luciferase assay in which
the maximal biophotonic luciferase signal was defined by target
cells plated with control T cells at the same densities (RLUmax,
maximal relative light unit). After 24, 48, or 72 hours, 0.14 mg
D‐luciferin (PerkinElmer Inc, Waltham, MA) was added per mL
medium in each well, and the biophotonic signal detected. The lysis
was determined as (1−[RLU sample/RLU max]) × 100 in relation to
treatment with control T cells. Serial tumor cell challenge was
conducted to mimic recursive antigen encounter on the basis of
published experimental set‐ups.17,36 SK‐N‐BE(2) neuroblastoma
cells and L1CAM‐CAR T cells were cocultured at a 1:2 E:T ratio
with nivolumab (or diluent, as control) added directly after
plating. At 4, 8, and 12 days, L1CAM‐CAR T cells were harvested
and the living cells quantified using a hemocytometer and
Trypan blue, before re‐plating in fresh media containing added
nivolumab or 0.9% NaCl with fresh SK‐N‐BE(2) neuroblastoma
cells (E:T ratio of 1:2). Cytotoxicity assay and FACS‐based
marker analysis were conducted 24 hours after rechallenge at
days 5, 9, and 12.
2.6 | In vitro cytokine release assay
For cytokine release assays, 2 × 105 T cells were seeded together
with tumor cells at a 2:1 E:T ratio. After 24 hours, conditioned media
was collected and stored at −80°C until analysis of IFNG using the
OptEIA enzyme‐linked immunosorbent assay (BD Biosciences) ac-
cording to the manufacturer's instructions.
2.7 | Flow cytometric marker and antigen detection
Cell surface expression of CD8A (cat#301041, BioLegend), L1CAM
(formerly CD171 cat #130‐100‐691, Miltenyi Biotec), PD‐1 (PDCD1,
cat #329922, BioLegend), PD‐L1 (CD274, cat #329708, BioLegend),
PTPRC isotopes CD45RO (cat #562641, BD Bioscience, Franklin
Lakes, NJ) and CD45RA (cat #304105, BioLegened), SELL (formerly
CD62L, cat #304821, BioLegend), and FAS (cat #305611, BioLegend)
were detected by fluorophore‐conjugated monoclonal antibodies on
a Fortessa X‐20 (BD Biosciences) 4‐laser fluorescence‐activated cell
sorter (FACS). EGFRt expression was detected using biotinylated
cetuximab (Bristol‐Myers Squibb) and phycoerythrin (PE)‐conjugated
streptavidin antibody (cat #12‐4317‐87, BioLegend). QuantiBRITE
PE calibration beads (BD Biosciences) were used to determine
L1CAM antigen density on neuroblastoma cells according to the
manufacturer's instructions. Briefly, QuantiBRITE PE calibration
beads conjugated with four different amounts of PE molecules were
used to generate a standard curve by comparing the geometric mean
of fluorescence intensity and amount of PE. Neuroblastoma cell lines
(200 000 neuroblastoma cells per well) were preincubated with PE‐
labeled monoclonal antibodies against L1CAM (Miltenyi Biotec) and
the signal acquired in FACS analysis with the same settings as for
QuantiBRITE PE beads. Antigen density at the cell surface for
L1CAM was calculated from the fluorescence intensity of stained
samples (geometric mean) using the standard curve. Flow cytometry
data was processed using FlowJo software (Tree Star Inc, Ash-
land, OR).
2.8 | Statistical analysis
Differences in cytotoxic activity, cell surface marker expression, and
intracellular cytokine expression between treatment groups and
controls in experiments were tested using paired or unpaired Student
t tests in GraphPad prism (GraphPad Software, La Jolla, CA).
P values < .05 were considered statistically significant.
3 | RESULTS
3.1 | L1CAM‐CAR T cell encounter upregulates
PD‐L1 on neuroblastoma cells and PD‐1/PD‐L1
expression in L1CAM‐CAR T cells
The PD‐1/PD‐L1 axis usually plays no role in high‐risk neuro-
blastomas due to low leukocyte infiltration of these immunological
rather cold tumors. Most tumor cells upregulate PD‐L1 surface ex-
pression in response to IFNG released by tumor‐specific T cells
(adaptive immune resistance).27 We tested whether the encounter
with neuroblastoma‐specific L1CAM‐targeting CAR T cells activates
the PD‐1/PD‐L1 axis in neuroblastoma cells in vitro, providing a ra-
tional to combine CAR T cells with checkpoint blockade to treat
neuroblastoma. To create a more challenging in vitro set‐up, we se-
lected three neuroblastoma cell lines expressing midrange or low
surface densities of the targeted L1CAM antigen. The SK‐N‐BE(2) cell
line expressed the median L1CAM level in the cell line panel ex-
amined using QuantiBRITE quantification, and low‐antigen levels
were expressed in the SH‐SY5Y and SK‐N‐AS cell lines (Figure 1A).
L1CAM‐specific second‐generation CAR T cells were generated from
TCM‐enriched CD8+ cells and comparable CAR expression was en-
sured by immunomagnetic selection for EGFRt (Figure S1). PD‐L1
expression was significantly induced in all three cell lines after co-
culture with T cells expressing the L1CAM‐targeting CAR but not
control T cells (Figure 1B). We hypothesized that PD‐L1 induction in
neuroblastoma cells was driven by soluble cytokines released by
activated L1CAM‐CAR T cells after tumor encounter. Media condi-
tioned by neuroblastoma cells alone, with L1CAM‐CAR or control
T cells for 24 hours was collected, then used to plate fresh neuro-
blastoma cells (Figure S2A). PD‐L1 expression was only induced by
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24‐hour exposure to medium conditioned by cocultured L1CAM‐
specific CAR T and neuroblastoma cells (Figure S2B). Furthermore,
we detected IFNG in the conditioned media of neuroblastoma/
L1CAM‐CAR T cell cocultures underlining the finding that soluble
factors rather than cell‐cell interactions contribute to PD‐L1 upre-
gulation in neuroblastoma cells (Figure S2C). PD‐1 expression also
increased on the L1CAM‐CAR T cell surface, and was most strongly
induced by SK‐N‐BE(2) cells (Figure 1C). Interestingly, increased
expression of the PD‐1 receptor was accompanied by increased
PD‐L1 ligand expression on the L1CAM‐CAR T cells after coculture
with all three neuroblastoma cell lines (Figure 1D). PD‐1‐mediated
inhibition of tumor‐infiltrating T cells could not only be caused by
tumor cells but potentially by PD‐L1‐expressing CAR T cells. Since we
demonstrated PD‐L1 expression in neuroblastoma cells was induced
by the soluble cytokine IFNG, we next investigated if this was also
true for PD‐L1 expression in L1CAM‐CAR T cells by adding either
IFNG or anti‐CD3/CD28 beads. Interestingly, only CD3/CD28 beads
but not IFNG induced PD‐L1 expression in L1CAM‐CAR T cells ex-
cluding cytokine‐mediated PD‐L1 induction for CAR T cells (Figure
S2D). Our data demonstrate that tumor/T cell encounter activated
the PD‐1/PD‐L1 axis in L1CAM‐targeting CAR T cells and
neuroblastoma cells and caused PD‐L1 upregulation on the CAR T
cells themselves.
3.2 | Nivolumab enhances L1CAM‐CAR T
cell‐directed neuroblastoma cell killing independent
of PD‐L1 expression on the tumor cells
Antibody‐based blockade of PD‐1 has been demonstrated to en-
hance CAR T cell efficacy in murine models for different solid
tumors.7,12 Having determined PD‐1/PD‐L1‐axis activation in both
L1CAM‐CAR T and neuroblastoma cells, we assessed whether
adding a monoclonal antibody against PD‐1 (nivolumab), could
boost L1CAM‐CAR T cell efficacy in vitro. The SK‐N‐BE(2), SH‐
SY5Y, and SK‐N‐AS cell lines were transduced with a GFP‐firefly
luciferase reporter plasmid to quantify viable tumor cells in the
luciferase‐based reporter assay. L1CAM‐specific CAR T cells were
cocultured with SK‐N‐BE(2) reporter cells in a 1:2 and 1:5 E:T ratio
with or without nivolumab. Cytotoxicity was assessed following 24,
48, and 72 hours of coculture by measuring the biophotonic signal
released by the remaining viable tumor cells. Nivolumab
F IGURE 1 L1CAM‐specific CAR T cell encounter activates the PD‐1/PD‐L1‐axis in neuroblastoma cells. A, Cell surface L1CAM density of
neuroblastoma cell lines obtained by flow cytometry. Chosen cell lines are framed. B, PD‐L1 surface expression of SK‐N‐BE(2), SH‐SY5Y, and
SK‐N‐AS neuroblastoma cells alone and after coculture with either control or L1CAM‐4‐1BB‐CAR T cells at a 1:5 effector:target (E:T) ratio for
24 hours. PD‐1 (C) and PD‐L1 expression (D) of central memory enriched control and L1CAM‐4‐1BB‐CAR T cells before and after coculture
with SK‐N‐BE(2) and SK‐N‐AS at a 1:1 E:T ratio or SH‐SY5Y neuroblastoma cells at a 1:5 E:T ratio, respectively for 24 hours. Data shown depicts
the mean expression from three independent experiments, *P < .05 and **P < .01 by unpaired (control compared with CAR T cells) or paired
(control, CAR T or tumor cells alone compared with cocultured cells) Student t test. CAR, chimeric antigen receptor; PD, programmed cell death
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significantly increased L1CAM‐CAR T cell‐directed killing of SK‐N‐
BE(2) cells in both effector to target ratios at all three‐time points
(Figure 2A). Cytotoxicity was more strongly enhanced by nivolumab
with the 1:5 E:T ratio, demonstrating an increasing benefit of PD‐1
blockade with enforced stress on L1CAM‐CAR T cells. Nivolumab
also significantly increased L1CAM‐CAR T cell‐directed killing
(1:5 E:T ratio after 24 hours) of SH‐SY5Y and SK‐N‐AS cells, which
expressed low‐antigen levels. We created neuroblastoma cells
expressing high PD‐L1 levels to test whether nivolumab required
PD‐L1 expression to enhance cytotoxicity. SK‐N‐BE(2) cells were
F IGURE 2 Nivolumab enhances neuroblastoma cell killing by L1CAM‐4‐1BB‐CAR T cells independently of PD‐L1 tumor cell expression
level. A, Cytotoxicity of L1CAM‐CAR T cells is determined by luciferase‐based killing assay following a tumor coculture for 24, 48, and 72 hours
at different E:T ratios and added nivolumab (or diluent, as control). Data shown depicts the mean cell lysis of three independent experiments,
previously assessing the median of each experiment's triplicates. *P < .05 and **P < .01 by two‐tailed paired t test. B, CAR T cell‐induced
cytotoxicity against SK‐N‐BE(2)PD‐L1+ after 24 hours at different E:T ratios ± nivolumab and flow cytometric quantification of PD‐L1 expression
on PD‐L1‐transduced SK‐N‐BE(2) cells. C, CAR T cell‐induced cytotoxicity against SK‐N‐BE(2)PD‐L1‐KO after 24 hours at different E:T
ratios ± nivolumab and flow cytometric quantification of PD‐L1 expression on PD‐L1‐knock down SK‐N‐BE(2) cells 24 hours after adding
100 ng/mL IFNG in relation to parental SK‐N‐BE(2) cells. CAR, chimeric antigen receptor; E:T, effector:target; IFNG, interferon gamma; PD,
programmed cell death
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lentivirally transduced with PD‐L1 to generated the SK‐N‐BE(2)PD‐L1+
neuroblastoma cell model (Figure 2B). Nivolumab significantly in-
creased L1CAM‐specific CAR T cell‐directed killing of PD‐L1‐
transduced SK‐N‐BE(2) cells in 1:2 and 1:5 E:T ratios after 24 hours.
However, cytotoxicity was similar in SK‐N‐BE(2) cells with or without
enforced PD‐L1 expression in the presence of nivolumab, speaking
against improved checkpoint inhibition response when tumor cells
express high PD‐L1 levels. PD‐L1 KO was generated using
CRISPR/Cas 9 in the SK‐N‐BE(2)PD‐L1‐KO model. PD‐L1
expression levels in SK‐N‐BE(2)PD‐L1‐KO were below 8% after IFNG
stimulation for 24 hours (Figure 2C). Nivolumab increased L1CAM‐
specific CAR T cell‐directed killing in the SK‐N‐BE(2)PD‐L1‐KO model at
the 1:2 but not 1:5 E:T ratio after 24 hours, indicating the benefit of
PD‐1 blockade remained despite minor PD‐L1 tumor expression. Our
data demonstrated that nivolumab‐enhancement of L1CAM‐CAR T
cell efficacy in vitro did not strictly correlate with PD‐L1 expression
levels on neuroblastoma cells as a ceiling effect could be observed
with enforced PD‐L1 expression. These findings imply PD‐1 mediated
inhibition and its blockade foremost depend on PD‐1 CAR T cell
expression.
3.3 | Central memory derivation drives strong
expression of PD‐1/PD‐L1‐axis in L1CAM‐CAR T cells
TCM‐derived CAR T cells persist longer in vivo,18,19 and when an
option, TCM are used as a source. However, the TCM cell fraction is
lower in pediatric than adult patients, making TCM‐derived CAR T cell
generation less often an option. Most ongoing pediatric CAR T cell
studies use bulk‐derived T cell products as starting material. L1CAM‐
CAR T cells were generated from the central memory fraction in
experiments conducted so far in this study, and to bring preclinical
testing closer to the clinical reality, we also compared L1CAM‐CAR T
cells from TCM stocks with bulk‐derived L1CAM‐CAR T cells using
our functional assays. Interestingly, PD‐1 blockade with nivolumab
did not enhance the cytotoxic activity of bulk‐derived L1CAM‐CAR T
F IGURE 3 Starting material for CAR T cell generation impacts nivolumab efficacy. A, Cytotoxicity of L1CAM‐CAR T cells derived from
either bulk‐ or TCM‐ cells is determined by luciferase‐based killing assay following a tumor coculture for 24 hours at a 1:2 E:T ratio and
added nivolumab (or diluent, as control). Cell lysis was determined and statistical analysis was performed as described in Figure 2. B, T cell
subsets in bulk‐ or TCM‐derived L1CAM‐4‐1BB‐CAR T cell populations, assessed on day 12 of rapid expansion by flow cytometry. Data
depicts the mean of three donors for bulk and TCM‐derived CAR T cells each. CD45RO+ CD62L− FAS+ for TEM‐like, CD45RO+ CD62L+
FAS+ for TCM‐like, CD45RA+ CD62L+ FAS+ for TSCM‐like, CD45RA+ CD62L+ FAS‐ for naïve‐like T cells. C, PD‐1 and PD‐L1 expression of
bulk‐ or TCM‐derived control and L1CAM‐4‐1BB‐CAR T cells before and after coculture with SK‐N‐BE(2) at a 1:1 E:T ratio for 24 hours. D,
PD‐L1 expression of SK‐N‐BE(2) neuroblastoma cells alone and after coculture with either bulk‐ or TCM‐derived L1CAM‐4‐1BB‐CAR
T cells at a 1:5 E:T ratio for 24 hours. Data depicts the mean of two donors for bulk and three donors for TCM‐derived CAR‐T cells,
respectively, with three independent experiments assessed for each donor, *P < .05 and **P < .01 were assessed by two‐tailed unpaired t
test, comparing TCM‐derived in relation to bulk‐derived control and CAR T cell PD‐1 and PD‐L1 expression. CAR, chimeric antigen
receptor; E:T, effector:target; PD, programmed cell death; TCM, central memory T cells
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cells against SK‐N‐BE(2) cells at a 1:2 E:T ratio after 24 hours
(Figure 3A). CAR T cell phenotype was flow cytometrically assessed
before their exposure to neuroblastoma cells in experiments to show
that the original phenotype was maintained during ex vivo expansion
of the bulk‐ or TCM‐derived CAR T cells. T cell subsets were defined
following the previously published approach by the Riddell group.37
Central memory‐like (CD45RO+/CD62L+ [SELL]/FAS+) CD8+ T cells
remained the biggest subset in TCM‐derived CAR T cells as expected
(Figure 3B). Bulk‐derived CAR T cells consisted mostly of effector
memory‐like (CD45RO+/CD62L−/FAS+) CD8+ T cell subsets. Induc-
tion of the PD‐1/PD‐L1 axis after 24 hours exposure to SK‐N‐BE(2)
cells (1:1 E:T ratio) was significantly higher in TCM‐derived L1CAM‐
CAR T cells than in their bulk‐derived counterparts (Figure 3C), and
PD‐1/PD‐L1 expression was also higher in TCM‐derived T cells before
tumor cell challenge. In addition to CD8+ L1CAM‐CAR T cells, higher
PD‐1 induction after 24 hours exposure to SK‐N‐BE(2) cells was also
seen for CD4+ TCM‐derived L1CAM‐CAR T cells compared with their
CD4+ bulk‐derived counterparts (Figure S3A). However, the induc-
tion of PD‐L1 in SK‐N‐BE(2) caused by CAR T cell encounter was
similar for bulk‐derived L1CAM‐CAR T cells and their TCM‐derived
counterparts (Figures 3D and S3B). Taken together, nivolumab did
not enhance the cytotoxic activity of bulk‐derived L1CAM‐CAR T
cells, most likely because PD‐1 and PD‐L1 induction in CAR T cells
themselves was only moderate and high PD‐1 and PD‐L1 CAR T cell
expression limited to the TCM‐derived subset of effector cells.
3.4 | CAR T cell subset but not CAR costimulatory
domain determines PD‐1 and PD‐L1 expression levels
Since the costimulatory domain of a CAR largely impacts CAR T cell
properties such as activation or persistence, we investigated its effect
on PD‐1/PD‐L1 upregulation in the L1CAM‐CAR T cells. The L1CAM‐
CAR T cells we have used so far harbor the 4‐1BB costimulatory
domain, and we will compare them with L1CAM‐targeting CAR T cells
harboring the CD28 costimulatory domain, which we refer to here as
L1CAM‐CD28‐CAR T cells. Similarly to what we observed for L1CAM‐
CAR T cells harboring the 4‐1BB costimulatory domain, induction of the
PD‐1/PD‐L1 axis was significantly higher after tumor cell encounter in
TCM‐derived L1CAM‐CD28‐CAR T cells compared with bulk‐derived
cells, and PD‐1/PD‐L1 was also higher in TCM‐derived L1CAM‐CD28‐
CAR T cells before tumor cell challenge (Figure 4A). The PD‐L1 upre-
gulation in SK‐N‐BE(2) was also similarly induced by coculture with
TCM‐ or bulk‐derived L1CAM‐CD28‐CAR T cells, and comparable with
PD‐L1 expression levels after coculture with 4‐1BB‐harboring L1CAM‐
CAR T cells (Figure 4B). Although L1CAM‐CD28‐CAR T cells expressed
higher PD‐1 levels than the 4‐1BB‐harboring L1CAM‐CAR T cells
before tumor cell encounter, and independently of their source T cell
subset (P < .01, data not shown), no significant difference in the
expression of the PD‐1/PD‐L1 axis was detected in L1CAM‐CAR T cells
harboring either costimulatory domain after tumor cell encounter.
Our data confirms the subset‐specific enhancement of PD‐1/PD‐L1
upregulation in TCM‐derived L1CAM‐CAR T cells and shows it is
independent of the type of costimulatory domain used in the CAR.
3.5 | Recursive tumor cell challenge reveals
enhanced L1CAM‐4‐1BB‐CAR T cell‐directed
neuroblastoma cell cytotoxicity by nivolumab
The PD‐1/PD‐L1‐axis is known to contribute to CAR T cell ex-
haustion when recursive rounds of tumor‐specific T cell activation
are necessary to achieve tumor eradication. We investigated how
PD‐1 checkpoint inhibition might assist in this scenario. Recursive
F IGURE 4 Enhanced PD‐1/PD‐L1 expression in TCM‐derived CAR T cells was independent of the costimulatory domain used. A, PD‐1 and
PD‐L1 expression of bulk‐ or TCM‐derived control and L1CAM‐CD28‐CAR T cells before and after coculture with SK‐N‐BE(2) at a 1:1 E:T ratio
for 24 hours. Data depicts the mean of two donors of bulk‐derived CAR T cells and two donors of TCM‐derived CAR T cells, respectively, with
three independent experiments assessed for each donor. *P < .05 and **P < .01 were assessed by two‐tailed unpaired t test, comparing
TCM‐derived in relation to bulk‐derived control and CAR T cell PD‐1 and PD‐L1 expression. B, PD‐L1 expression of SK‐N‐BE(2) neuroblastoma
cells alone and after coculture with either bulk‐ or TCM‐derived L1CAM‐CD28‐CAR T cells at a 1:5 E:T ratio for 24 hours. Data depicts the mean
of two donors each for bulk‐ or TCM‐derived CAR T cells, with three independent experiments assessed for each donor. CAR, chimeric antigen
receptor; E:T, effector:target; PD, programmed cell death; TCM, central memory T cells
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tumor encounter was mimicked by maintaining CAR T and tumor
cell interactions throughout 13 days. CAR T cells were re-
challenged with fresh SK‐N‐BE(2) cells three times during the
13‐day period at a 1:2 E:T ratio following a previously published
strategy17,36 (Figure 5A). Only TCM‐derived CAR T cells were used
in these experiments because of their stronger expression of the
PD‐1/PD‐L1 axis following tumor cell challenge. PD‐1 expression
was significantly induced by all three tumor cell rechallenges in
both second‐generation L1CAM‐targeting CAR T cells. In contrast
to our previous findings, where after single tumor encounter no
significant difference in PD‐1 expression levels between L1CAM‐
CAR T cells with either CD28 or a 4‐1BB costimulatory domain
was observed, the PD‐1 expression levels in L1CAM‐CD28‐CAR T
cells were persistently higher during recursive tumor cell en-
counter (36.8%, 38.0%, and 49.0% in L1CAM‐CD28‐CAR T cells vs
21.3%, 14.6%, and 15.1% in L1CAM‐4‐1BB‐CAR T cells, respec-
tively; Figure 5B). To see if cotreatment with nivolumab has an
influence on the CAR T cell phenotype, we cocultured and re-
challenged the CAR T cells in the presence or absence of nivolu-
mab and analyzed the cells after 12 days for expression of
CD45RO, CD45RA, CD62L, and FAS using flow cytometry. Both
L1CAM‐CAR T cell populations, either with CD28 or 4‐1BB as
costimulatory domain, shifted phenotypically towards an effector‐
memory‐like type over the course of the serial tumor challenge
irrespective of nivolumab (Figure 5C). Next, we wanted to in-
vestigate PD‐1 blockade mediated enhancement of TCM‐derived
L1CAM‐CAR T cell killing in the context of T cell exhaustion mi-
micked by our serial tumor challenge. Cytotoxic activity of
L1CAM‐CAR T cells was determined by the luciferase‐based re-
porter assay when subsequently cocultured with new SK‐N‐BE(2)
at a 1:1 E:T ratio after each rechallenge. Despite the higher PD‐1
expression observed in L1CAM‐CD28‐CAR T cells, tumor cell lysis
was only significantly enhanced by PD‐1 blockade for L1CAM‐4‐
1BB‐CAR T cells after the third rechallenge (Figure 5D). Notably,
the killing efficacy of L1CAM‐4‐1BB‐CAR T cells decreased by
almost 50% with each tumor encounter, which we did not observe
for L1CAM‐CD28‐CAR T cells to that extent. The nivolumab‐
enhancement of neuroblastoma cell killing was not reflected by
increased numbers of cytokine‐producing T cells or lower apop-
tosis rates at the end of the serial tumor challenge (data not
F IGURE 5 Nivolumab requires CAR T cell exhaustion additional to high PD‐1 and PD‐L1 CAR T cell expression. A, A schematic overview of
the serial tumor challenge with three rechallenges of freshly added SK‐N‐BE(2) neuroblastoma cells at a 1:2 E:T ratio. B, PD‐1 expression
of TCM‐derived L1CAM‐4‐1BB‐ and CD28‐CAR T cells 24 hours after rechallenge. **P < .01 were assessed by two‐tailed unpaired t test,
comparing TCM‐derived in relation to bulk‐derived control and CAR T cell PD‐1 expression. C, T cell subsets of TCM‐derived L1CAM‐4‐1BB‐ or
CD28‐CAR T cell populations before and at day 12 of the serial tumor challenge. CD45RO+ CD62L− FAS+ for TEM‐like, CD45RO+ CD62L+ FAS+
for TCM‐like, CD45RA+ CD62L+ FAS+ for TSCM‐like, CD45RA+ CD62L+ FAS‐ for naïve‐like T cells. D, Neuroblastoma cell killing of TCM‐derived
L1CAM‐4‐1BB‐ or CD28‐CAR T cells 24 hours after rechallenge with SK‐N‐BE(2) neuroblastoma cells at a 1:1 E:T ratio with added nivolumab
(or diluent, as control). Cell lysis was determined and statistical analysis was performed as described in Figure 2. *P < .05. CAR, chimeric antigen
receptor; E:T, effector:target; PD, programmed cell death; TCM, central memory T cells
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shown). Nonetheless, cotreatment with nivolumab during re-
cursive tumor cell encounters enhances L1CAM‐CAR T cell‐
directed neuroblastoma cell killing especially in CAR T cells har-
boring the costimulatory domain 4‐1BB.
4 | DISCUSSION
Combining CAR T cell therapy with complementing immunotherapies
such as PD‐1 checkpoint blockade is a promising treatment approach
for solid tumors. Here, we analyzed activation of the PD‐1/PD‐L1
axis during in vitro testing of neuroblastoma‐specific CAR T cell
products and assessed the impact of combining CAR T cell therapy
and checkpoint blockade with nivolumab. We demonstrate that the
PD‐1/PD‐L1 axis was induced in neuroblastoma cells after L1CAM‐
CAR T cell encounter. Furthermore, we show that nivolumab‐
enhanced L1CAM‐CAR T cell‐directed cytotoxicity relied on strong
PD‐1/PD‐L1 expression in the CAR T cells themselves, which in turn
depended on the type of costimulatory domain in the CAR construct
and strongly on the T cell subset from which the CAR T cells were
generated.
For PD‐1 checkpoint blockade to assist CAR T cell therapeutic
efficacy, PD‐1 must be present on CAR T cells and its ligand, PD‐L1,
must be present on the neuroblastoma cells. PD‐L1 expression in
diagnostic neuroblastoma biopsies varies in recently published
studies. Reports span the complete absence of PD‐L1 in 18 neuro-
blastoma samples at diagnosis reported by Aoki et al38 to
PD‐L1 expression in 14% of 118 mainly diagnostic neuroblastoma
samples.39 We demonstrate that neuroblastoma‐specific CAR T cells
induced PD‐L1 expression in three neuroblastoma cell lines that
expressed minor levels of PD‐L1 ligand before CAR T cell encounter.
We draw the conclusion that even if PD‐L1 is often not expressed on
the neuroblastoma cells at diagnosis, this may change at the time of
treatment and is likely not to be the case after CAR T cell exposure,
meaning that PD‐L1 expression in diagnostic samples should not be
used to determine whether to apply a combinational approach using
CAR T cells and PD‐1 checkpoint inhibition in patients.
To date, PD‐1/PD‐L1‐axis disruption only proved advantageous
for in vitro and in vivo preclinical testing in different solid tumor
models if combined with CAR T cells strongly expressing PD‐1.6‐8 First
results from an ongoing phase 1 trial (NCT01822652) for high‐risk and
relapsed neuroblastoma showed no effect of additional PD‐1 blockade
on expansion or persistence of third generation iC9‐GD2‐CAR T cells.
PD‐1 expression in CD8+‐CAR T cells before transfusion was com-
paratively low.24 Unfortunately, PD‐1 expression in CAR T cells after
transfusion was not measured by the authors precluding to call the
low PD‐1 expression to account for the missing benefit of additional
PD‐1 blockade. In a recent study, the benefit of combining PD‐1
blockade with CAR T cell therapy for neuroblastoma lessened with
incorporating IL‐15 signaling into GD2‐targeting CAR T cells likely due
to reduced PD‐1 expression levels in these modified CAR T cells.40
Concordantly, we demonstrate that nivolumab only enhanced the
cytotoxic activity of L1CAM‐CAR T cells with high PD‐1 expression.
Host immune cells such as myeloid‐derived suppressor cells and
tumor‐infiltrating lymphocytes that express PD‐L1 themselves have
been shown to contribute to immune escape in solid tumor
models.41,42 In evaluating the response in patients with different
cancers to a monoclonal antibody against PD‐L1, Herbst et al43 de-
termined that PD‐L1 expression on tumor cells positively correlated
with treatment efficacy and that PD‐L1 expression on tumor‐
infiltrating lymphocytes was predictive for higher response rates. We
observed that tumor cell encounter increased PD‐L1 expression on
L1CAM‐CAR T cells. In spite of minor tumor‐expressed PD‐L1 levels
to inhibit CAR T cell cytotoxic activity by binding PD‐1, a tendency
towards nivolumab‐enhanced L1CAM‐CAR T cell efficacy persisted
when cocultured with PD‐L1 KO SK‐N‐BE(2) cells. We consider CAR‐
on‐CAR and not only tumor‐on‐CAR inhibition to factor into the PD‐
1/PD‐L1‐conveyed inhibition of antitumor efficacy.
TCM‐derived CAR T cells have been demonstrated to persist
longer and proliferate more in patients.18‐20 Comparing bulk and
TCM‐derived CAR T cells, we found differences in PD‐1 expression.
Higher PD‐1 expression in TCM‐derived L1CAM‐CAR T cells was
independent of the type of costimulatory domain used in the CAR
construct and persisted over repeated tumor cell encounters. En-
amorado et al44 demonstrated that CAR T cells derived from TCM‐
enriched cell subpopulations strongly expressed PD‐1 expression,
had antitumor activity and formed a resident memory T cell subset
following tumor challenge. Notably, PD‐1 blockade enhanced TCM
cell infiltration and augmented antitumor immunity. Rather than
being a hindrance, an activated PD‐1/PD‐L1‐axis in TCM‐derived CAR
T cells is an innate quality on which we can capitalize to further
augment their therapeutic efficacy.
How the CD28 costimulatory domain impacts CAR T cell func-
tion remains controversially discussed in the literature. Induction of
PD‐1 and PD‐L1 after recursive tumor cell challenge was higher in
our L1CAM‐targeting CAR T cells with the CD28 instead of the
4‐1BB costimulatory domain. Zolov et al30 showed that the CD28
costimulatory domain rendered their CD123‐targeting CAR T cells
more susceptible to PD‐1/PD‐L1‐mediated inhibition of T cell acti-
vation despite lower PD‐1 expression. In line with these findings, the
CD28 costimulatory receptor, as compared with the T cell receptor
signaling cascade, was preferentially targeted by PD‐1/PD‐L1‐
mediated inhibition through downstream PD‐1‐activated Shp2
phosphatase.45 In a mouse model for chronic infection, a proliferation
of exhausted CD8+ T cells induced by monoclonal antibody‐based
PD‐1 blockade was dependent on CD28.46 Contrarily, targeted CD28
deletion in coculture systems of T cells and antigen‐presenting cells
has demonstrated that the costimulatory receptor is unnecessary for
PD‐1/PD‐L1‐conveyed inhibition of T cell receptor signaling.47 Fur-
thermore, Mizuno et al47 showed that CD28 costimulatory signaling
rather attenuated PD‐1/PD‐L1‐mediated inhibition of T cell activa-
tion. Similarly, the higher PD‐1 expression in our CD28‐harboring
L1CAM‐targeting CAR T cells did not translate to nivolumab‐driven
enhanced cytotoxic activity following neuroblastoma cell challenge.
Contrarily, nivolumab significantly enhanced cytotoxic activity in our
4‐1BB‐harboring L1CAM‐targeting CAR T cells during simulated
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recursive tumor cell encounter despite the lower PD‐1 expression.
Since cytotoxic activity was lower and declined more quickly with
recursive tumor encounter in these CAR T cells, exhaustion rendered
them more susceptible to nivolumab‐mediated enhancement. Our
findings are in line with prior reports observing higher CD28‐related
PD‐1 expression in CAR T cells, but question a straightforward un-
derstanding of the interplay between the costimulatory domain and
PD‐1/PD‐L1 signaling axis.
Our data support that PD‐1 blockade augments TCM‐derived
L1CAM‐CAR T cell efficacy against neuroblastoma. L1CAM‐CAR T
cell encounter induced PD‐L1 expression on neuroblastoma cells,
confirming adaptive immune resistance. However, PD‐L1 expression
on tumor cells did not strictly correlate with nivolumab‐enhancement
of L1CAM‐CAR T cell cytotoxic activity. Therefore, PD‐1 blockade
did not solely depend on PD‐L1 tumor expression levels in our model.
T cell source, and to a lesser extent costimulatory domain type, for
CAR T cell generation impacted PD‐1/PD‐L1 expression on L1CAM‐
CAR T cells, which in turn drove nivolumab‐enhancement. Thus,
T cell subset selection and prescreening CAR T cells for PD‐1/PD‐L1
expression, then combining only CAR T cells expressing higher PD‐1/
PD‐L1 levels with nivolumab, could improve CAR T cell therapy
treatment efficacy through more informed treatment combinations.
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